Patents Assigned to Xigen Inflammation Ltd.
-
Patent number: 11779628Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling.Type: GrantFiled: October 8, 2015Date of Patent: October 10, 2023Assignee: XIGEN INFLAMMATION LTD.Inventors: Jean-Marc Combette, Catherine Deloche
-
Patent number: 11331364Abstract: The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.Type: GrantFiled: June 4, 2019Date of Patent: May 17, 2022Assignee: XIGEN INFLAMMATION LTD.Inventors: Jean-Marc Combette, Catherine Deloche
-
Patent number: 10967038Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scieritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc.Type: GrantFiled: March 23, 2018Date of Patent: April 6, 2021Assignee: Xigen Inflammation Ltd.Inventors: Jean-Marc Combette, Catherine Deloche, Claire Abadie
-
Patent number: 10624948Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling.Type: GrantFiled: June 26, 2014Date of Patent: April 21, 2020Assignee: XIGEN INFLAMMATION LTD.Inventors: Jean-Marc Combette, Catherine Deloche
-
Patent number: 10596223Abstract: The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.Type: GrantFiled: July 22, 2016Date of Patent: March 24, 2020Assignee: Xigen Inflammation Ltd.Inventors: Jean-Marc Combette, Catherine Deloche
-
Publication number: 20190337988Abstract: The present invention relates to novel transporter constructs of the generic formula (I) DlLLLxDm(LLLyDn)a and variants thereof. The present invention also refers to transporter cargo conjugate molecules, particularly of conjugates of the novel transporter constructs with a cargo moiety, e.g. proteins or peptides, nucleic acids, cytotoxic agents, organic molecules, etc. The present invention furthermore discloses (pharmaceutical) compositions comprising these conjugates and methods of treatment and uses involving such transporter constructs.Type: ApplicationFiled: December 17, 2018Publication date: November 7, 2019Applicant: Xigen Inflammation Ltd.Inventor: Christophe Bonny
-
Publication number: 20190060392Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scieritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc.Type: ApplicationFiled: March 23, 2018Publication date: February 28, 2019Applicant: Xigen Inflammation Ltd.Inventors: Jean-Marc Combette, Catherine Deloche, Claire Abadie
-
Patent number: 10023615Abstract: The present invention relates to the use of specific transporter cargo conjugate molecules for the transport of a substance of interest (cargo molecule) into white blood cells. Said transporter cargo conjugate molecules may be used for the treatment, prophylaxis, attenuation and/or amelioration of a disease and/or disorder involving white blood cells. The present invention also relates to manufacture of said transporter cargo conjugate molecules, to a method of transporting a substance of interest (cargo) into a white blood cell and to a white blood cell comprising said transporter cargo conjugate molecules or fragments thereof.Type: GrantFiled: December 22, 2009Date of Patent: July 17, 2018Assignee: Xigen Inflammation Ltd.Inventor: Christophe Bonny
-
Patent number: 9624267Abstract: Inhibitor molecules for c-Jun N-terminal kinase (JNK) are described. Furthermore, methods for raising antibodies against such inhibitor molecules as well as antibodies raised by such methods and cells producing the antibodies are also described.Type: GrantFiled: February 4, 2015Date of Patent: April 18, 2017Assignee: Xigen Inflammation Ltd.Inventor: Christophe Bonny
-
Patent number: 9610330Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling, wherein these diseases or disorders are selected from autoimmune disorders, cardiovascular diseases, cancerous diseases, diabetes, including diabetes type 1 or type 2, inflammatory diseases, hair loss, including Alopecia areata, diseases of the lung, neuronal or neurodegenerative diseases, diseases of the liver, diseases of the spine, diseases of the uterus, viral infectious diseases and depressive disorders.Type: GrantFiled: March 6, 2015Date of Patent: April 4, 2017Assignee: Xigen Inflammation Ltd.Inventor: Christophe Bonny
-
Publication number: 20160264630Abstract: Protein kinase inhibitors and more specifically inhibitors of the protein kinase c-Jun amino terminal kinase are herein described. Additionally, JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling are herein provided.Type: ApplicationFiled: February 16, 2016Publication date: September 15, 2016Applicant: XIGEN INFLAMMATION LTD.Inventor: Christophe Bonny
-
Publication number: 20160089413Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scieritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc.Type: ApplicationFiled: September 9, 2015Publication date: March 31, 2016Applicant: XIGEN INFLAMMATION LTD.Inventors: JEAN-MARC COMBETTE, CATHERINE DELOCHE, CLAIRE ABADIE
-
Patent number: 9290538Abstract: Protein kinase inhibitors and more specifically inhibitors of the protein kinase c-Jun amino terminal kinase are herein described. Additionally, JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling are herein provided.Type: GrantFiled: December 31, 2013Date of Patent: March 22, 2016Assignee: Xigen Inflammation Ltd.Inventor: Christophe Bonny
-
Patent number: 9180159Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory digestive diseases, such as colitis, including e.g. Ulcerative colitis, Crohn's disease, diversion colitis, ischemic colitis, infectious colitis, fulminant colitis, chemical colitis, microscopic colitis, lymphocytic colitis, and atypical colitis, etc.Type: GrantFiled: June 2, 2009Date of Patent: November 10, 2015Assignee: Xigen Inflammation Ltd.Inventor: Christophe Bonny
-
Patent number: 9150618Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scleritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc.Type: GrantFiled: October 14, 2010Date of Patent: October 6, 2015Assignee: Xigen Inflammation Ltd.Inventors: Jean-Marc Combette, Catherine Deloche, Claire Abadie
-
Patent number: 9006185Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling, wherein these diseases or disorders are selected from autoimmune disorders, cardiovascular diseases, cancerous diseases, diabetes, including diabetes type 1 or type 2, inflammatory diseases, hair loss, including Alopecia areata, diseases of the lung, neuronal or neurodegenerative diseases, diseases of the liver, diseases of the spine, diseases of the uterus, viral infectious diseases and depressive disorders.Type: GrantFiled: June 2, 2009Date of Patent: April 14, 2015Assignee: Xigen Inflammation Ltd.Inventor: Christophe Bonny
-
Patent number: 8981052Abstract: JNK inhibitor molecules are described. In addition, methods for raising antibodies against such JNK inhibitor molecules are disclosed. These antibodies and cells producing these antibodies are also described.Type: GrantFiled: June 21, 2011Date of Patent: March 17, 2015Assignee: Xigen Inflammation Ltd.Inventor: Christophe Bonny
-
Publication number: 20140200187Abstract: The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling.Type: ApplicationFiled: December 31, 2013Publication date: July 17, 2014Applicant: XIGEN INFLAMMATION LTD.Inventor: Christophe Bonny
-
Patent number: 8748395Abstract: Protein kinase inhibitors and more specifically inhibitors of the protein kinase c-Jun amino terminal kinase are described. Additionally, JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling are described.Type: GrantFiled: September 12, 2006Date of Patent: June 10, 2014Assignee: Xigen Inflammation Ltd.Inventor: Christophe Bonny